|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.0082 - 0.0090|
|52 Week Range||0.0082 - 0.1300|
|Beta (3Y Monthly)||-4.76|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Houston, TX, March 06, 2019 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company is excited about recent news of accomplishments of Diabetes Relief.
DALLAS , Dec. 28, 2018 /PRNewswire/ -- eQuine Holdings, a Class II Multi-Family Office, has disclosed an eight percent (8%) equity stake in AngioSoma (OTC-PINK:SOAN). On December 17, 2018 AngioSoma announced ...
Houston, TX, Dec. 14, 2018 -- via NEWMEDIAWIRE -- AngioSoma, Inc. (OTC: SOAN) announced today the Company has entered into a partially binding letter of intent to acquire 100%.
Peripheral Artery Disease Device Manufacturer Targeted for Joint Venture HOUSTON, Nov. 13, 2018 -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading biotechnology research.
New Industry Data and Product Roadmap Align for Optimistic Outlook HOUSTON, Nov. 08, 2018 -- via NEWMEDIAWIRE -- AngioSoma (OTC: SOAN), a leading biotechnology research and.
The site, YouthfulBrilliance.com, features products within the Nutraceutical and Cosmeceutical industries currently with a future roadmap to expand product offerings with key partnerships and their growing Amazon storefront. AngioSoma is optimistic the new site launch paired with a new, innovative marketing plan will provide a solid foundation to continue research and development of new product lines designed to enhance lives. “The new YouthfulBrilliance.com sub-brand and website exemplifies AngioSoma’s innovative approach to the market and our unique target audience with a feature rich ecommerce site that sets the foundation for our future growth plans,” says Alex Blankenship, president of AngioSoma.
AngioSoma (SOAN) today announced they will organize the business into three new business units to meet specific and emerging market opportunities: Pharmaceuticals, Nutraceuticals, and Cosmeceuticals. “We have made great strides in the past six months to leverage our growing market strength and operational efficiencies,” said AngioSoma president and chief executive officer, Alex Blankenship. The first new division, Pharmaceuticals, focused exclusively on delivering innovative pharma-based solutions for the rapidly-growing, multi-billion-dollar medical market, will provide industry-leading research and development to provide treatment for many serious medical problems.
Original StemStrength™ was designed for men only but AngioSoma is excited to reveal the new StemStrength™ will be for both Women and Men, plus it will come in an AM and PM formulation. AngioSoma is excited to continue to innovate for its customers across the spectrum of health-related products.
We are pleased to announce we have initiated our new website, http://www.soma-ceuticals.com to market our SomaceuticalsTM line of health supplements. Our innovative supplements cover three industry segments: nutraceuticals, cosmeceuticals, and pharmaceuticals.